CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ:DYAX) today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR® (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
